Skip to main content

Table 3 Comparison of neoadjuvant trials in lung cancer

From: Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

Trial Phase TNM Population Regimen Sample RR
Chemotherapy       
Roth 1994 [21] II IIIA Total CEP 28 35 %
Rosell 1994 [20] II IIIA Total MIC 30
Scagliotti 2012 [19] (CHEST) III I-IIIA Total GC 129 35.4 %
TKI       
Lara-Guerra 2009 [13] II I Total G 36 11 %
  II I Mut EGFR G 6 50 %
Schaake 2012 [14] II I-IIIA Total E 60 5 %
  II I-IIIA Enriched E 29 34 %
Chemo-TKI       
Lu 2013 [22] (CTONG 1101) II IIIA-N2 Enriched E + GC 39 46 %
Bio-maker guided       
Zhong 2014 (CSLC 0702) II IIIA-N2 Total E or GC 24 42 %
II IIIA-N2 Mut EGFR E 12 58.3 %
II IIIA-N2 WT-EGFR GC 12 25 %
  1. CEP cyclophosphamide/etoposide/cisplatin, MIC mitomycin/ifosfamide/cisplatin, GC gemcitabine/carboplatin, E erlotinib, G gefitinib, TKI tyrosine kinase inhibitor, RR response rate, EGFR epidermal growth factor receptor, Mut mutant, WT wild type